Hesperetin attenuates the expression of markers of adipose tissue fibrosis in pre-adipocytes.
Adipose tissue fibrosis
Collagen
Hesperetin
Matrix metalloproteinase
Obesity
Osteopontin
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
11 Sep 2023
11 Sep 2023
Historique:
received:
12
03
2023
accepted:
04
09
2023
medline:
13
9
2023
pubmed:
12
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Excessive extracellular matrix (ECM) deposition in adipose tissue is a hallmark of fibrosis, leading to disrupted adipose tissue homeostasis and metabolic dysfunction. Hesperetin, a flavonoid compound, has shown promising anti-inflammatory, anti-obesity and anti-diabetic properties. Therefore, we investigated the anti-fibrotic effects of hesperetin, through targeting ECM components and matrix metalloproteinase enzymes. 3T3-L1 cells were cultured in DMEM, containing 10% FBS and 1% penicillin/streptomycin. Cells were treated with a range of hesperetin concentrations, and the cell viability was determined using MTT assay. Subsequently, the expression of genes encoding collagen VI, osteopontin, matrix metalloproteinase-2 (Mmp-2) and Mmp-9 was analyzed using specific primers and real-time PCR technique. To evaluate protein levels of collagen VI and osteopontin, Western blotting was performed. Hesperetin affected the viability of 3T3-L1 adipocytes with IC50 of 447.4 µM, 339.2 µM and 258.8 µM (24 h, 48 and 72 h, respectively). Hesperetin significantly reduced the gene and protein expression of both collagen VI and osteopontin in 3T3-L1 pre-adipocytes, in a time- and dose-dependent manner. Hesperetin was also able to cause a remarkable decline in gene expression of Mmp2 and Mmp9. Hesperetin could potently reduce the production of markers of adipose tissue fibrosis and might be considered a potential anti-fibrotic compound in obesity. Thus, hesperetin has the potency to be used for the treatment of obesity-associated fibrosis.
Sections du résumé
BACKGROUND
BACKGROUND
Excessive extracellular matrix (ECM) deposition in adipose tissue is a hallmark of fibrosis, leading to disrupted adipose tissue homeostasis and metabolic dysfunction. Hesperetin, a flavonoid compound, has shown promising anti-inflammatory, anti-obesity and anti-diabetic properties. Therefore, we investigated the anti-fibrotic effects of hesperetin, through targeting ECM components and matrix metalloproteinase enzymes.
METHODS
METHODS
3T3-L1 cells were cultured in DMEM, containing 10% FBS and 1% penicillin/streptomycin. Cells were treated with a range of hesperetin concentrations, and the cell viability was determined using MTT assay. Subsequently, the expression of genes encoding collagen VI, osteopontin, matrix metalloproteinase-2 (Mmp-2) and Mmp-9 was analyzed using specific primers and real-time PCR technique. To evaluate protein levels of collagen VI and osteopontin, Western blotting was performed.
RESULTS
RESULTS
Hesperetin affected the viability of 3T3-L1 adipocytes with IC50 of 447.4 µM, 339.2 µM and 258.8 µM (24 h, 48 and 72 h, respectively). Hesperetin significantly reduced the gene and protein expression of both collagen VI and osteopontin in 3T3-L1 pre-adipocytes, in a time- and dose-dependent manner. Hesperetin was also able to cause a remarkable decline in gene expression of Mmp2 and Mmp9.
CONCLUSION
CONCLUSIONS
Hesperetin could potently reduce the production of markers of adipose tissue fibrosis and might be considered a potential anti-fibrotic compound in obesity. Thus, hesperetin has the potency to be used for the treatment of obesity-associated fibrosis.
Identifiants
pubmed: 37697354
doi: 10.1186/s12906-023-04152-z
pii: 10.1186/s12906-023-04152-z
pmc: PMC10496229
doi:
Substances chimiques
hesperetin
Q9Q3D557F1
Matrix Metalloproteinase 2
EC 3.4.24.24
Osteopontin
106441-73-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
315Subventions
Organisme : Iran University of Medical Sciences
ID : 1400-1-4-19488
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Nutrients. 2021 Jul 11;13(7):
pubmed: 34371884
Eur J Pharmacol. 2022 Jan 15;915:174530
pubmed: 34902361
Biochem Biophys Res Commun. 2010 Apr 9;394(3):728-32
pubmed: 20230793
Int J Mol Sci. 2020 Aug 04;21(15):
pubmed: 32759639
Food Funct. 2021 May 11;12(9):3898-3918
pubmed: 33977953
Int Immunopharmacol. 2019 Nov;76:105838
pubmed: 31473406
Endothelium. 2008 Jul-Aug;15(4):219-24
pubmed: 18663625
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282827
Endocrinology. 2011 Jun;152(6):2219-27
pubmed: 21467192
Nat Commun. 2022 Oct 13;13(1):6030
pubmed: 36229481
BMC Physiol. 2012 Apr 02;12:4
pubmed: 22471305
Cell Metab. 2018 Jan 9;27(1):180-194.e6
pubmed: 29320702
Acta Pharmacol Sin. 2022 Feb;43(2):367-375
pubmed: 33875797
Food Sci Biotechnol. 2018 Nov 2;28(3):873-879
pubmed: 31093446
Biomed Pharmacother. 2018 Jan;97:98-106
pubmed: 29080465
J Clin Endocrinol Metab. 2007 Sep;92(9):3719-27
pubmed: 17595250
Biomed Pharmacother. 2018 Sep;105:121-129
pubmed: 29852389
Sci Rep. 2021 Oct 8;11(1):20052
pubmed: 34625635
RSC Adv. 2018 Jul 6;8(43):24434-24443
pubmed: 35539191
J Agric Food Chem. 2018 Sep 19;66(37):9679-9689
pubmed: 30183290
Cytokine. 2020 Oct;134:155193
pubmed: 32707422
Chem Biodivers. 2022 Apr;19(4):e202100960
pubmed: 35266608
Nutrients. 2020 Aug 05;12(8):
pubmed: 32764233
Food Funct. 2017 Oct 18;8(10):3576-3586
pubmed: 28884178
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Nutrients. 2020 Nov 14;12(11):
pubmed: 33202550
Nutrients. 2018 Dec 28;11(1):
pubmed: 30597847
FEBS J. 2022 Jul;289(13):3603-3629
pubmed: 34109754
World J Diabetes. 2015 May 15;6(4):548-53
pubmed: 25987952
J Biochem Mol Toxicol. 2022 Oct;36(10):e23149
pubmed: 35712856
Biomarkers. 2022 Dec;27(8):784-794
pubmed: 36083032
Lipids Health Dis. 2011 Feb 23;10:36
pubmed: 21345233
Clin Chim Acta. 2003 Jan;327(1-2):129-37
pubmed: 12482628
Nat Commun. 2014 Mar 19;5:3485
pubmed: 24647224
J Clin Invest. 2007 Oct;117(10):2877-88
pubmed: 17823662
Mol Cell Biol. 2009 Mar;29(6):1575-91
pubmed: 19114551
J Clin Invest. 2019 Oct 1;129(10):3978-3989
pubmed: 31524630
Curr Obes Rep. 2020 Sep;9(3):219-230
pubmed: 32594318
Biomol Ther (Seoul). 2013 Mar;21(2):121-5
pubmed: 24009869
Int J Mol Sci. 2020 Aug 21;21(17):
pubmed: 32825788
PLoS One. 2014 May 28;9(5):e98398
pubmed: 24871103